The arginine methyltransferase PRMT5-MEP50 is required for embryogenesis and is misregulated in many cancers. PRMT5 targets a wide variety of substrates, including histone proteins involved in specifying an epigenetic code. However, the mechanism by which PRMT5 utilizes MEP50 to discriminate substrates and to specifically methylate target arginines is unclear. To test a model in which MEP50 is critical for substrate recognition and orientation, we determined the crystal structure of Xenopus laevis PRMT5-MEP50 complexed with S-adenosylhomocysteine (SAH). PRMT5-MEP50 forms an unusual tetramer of heterodimers with substantial surface negative charge. MEP50 is required for PRMT5-catalyzed histone H2A and H4 methyltransferase activity and binds substrates independently. The PRMT5 catalytic site is oriented towards the cross-dimer paired MEP50. Histone peptide arrays and solution assays demonstrate that PRMT5-MEP50 activity is inhibited by substrate phosphorylation and enhanced by substrate acetylation. Electron microscopy and reconstruction showed substrate centered on MEP50. These data support a mechanism in which MEP50 binds substrate and stimulates PRMT5 activity modulated by substrate post-translational modifications.

Background: PRMT5-MEP50 is an arginine methyltransferase with significant roles in development and cancer. Results: MEP50 binds to the histone fold domain and is essential for the efficient use of SAM by PRMT5. Conclusion: MEP50 is essential for methylation of histones H4 and H2A by PRMT5. Significance: The mechanism of histone methylation by PRMT5-MEP50 provides novel insight into methyltransferase mechanisms and therapeutic development.

Background: Histones are specifically modified in the Xenopus egg. Results: A complex of Prmt5 and Mep50 methylates histones H2A and H4 and the histone chaperone nucleoplasmin on an arginine in a conserved motif. Conclusion: Arginine methylation is enriched in the egg and targets chromatin-acting proteins. Significance: Histone arginine methylation probably results in specification of the pluripotent developmental program.